ArticleMMWR. Morbidity and mortality weekly report2013
Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users.
Article in MMWR. Morbidity and mortality weekly report, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03617874 (PC4PrEP), which is not on this map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PC4PrEP: Integrating Pre-Exposure Prophylaxis (PrEP) Into Primary Care
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials.Journal of acquired immune deficiency syndromes (1999) · 2016Pooled it
- Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Trial
- Trial
- "I Just Need Guidance Through This Maze I'm Going Through": Addressing Unmet Basic and Mental Health Needs to Facilitate Engagement in HIV Prevention Services in the Context of Stimulant Use.AIDS patient care and STDs · 2026Article
- Investigating facilitators and barriers to the routine provision of HIV PrEP in community pharmacies in London.BMC health services research · 2025Article
- Facilitators and Barriers to Implementing HIV Testing and Pre-Exposure Prophylaxis in Substance Use Treatment Programs: Perspectives of Non-medical Staff.Substance use & addiction journal · 2024Article
- Uptake of Human Papillomavirus Vaccination by HIV Status and HIV Pre-exposure Prophylaxis (PrEP) Care Engagement Among Young Sexual Minority Men 17-24 Years Old in the USA.Sexuality research & social policy : journal of NSRC : SR & SP · 2022Article
- A Narrative Review of Continuing Professional Development Needs for Pharmacists with Respect to Pre-exposure Prophylaxis (PrEP) for Human Immunodeficiency Virus (HIV).Pharmacy (Basel, Switzerland) · 2020Review
- Associations between recent thymic emigrants and CD4+ T-cell recovery after short-term antiretroviral therapy initiation.AIDS (London, England) · 2020Article
- HIV Pre-Exposure Prophylaxis Prevention Awareness, Willingness, and Perceived Barriers among People Who Inject Drugs in Los Angeles and San Francisco, CA, 2016-2018.Substance use & misuse · 2020Article
- US Guideline Criteria for Human Immunodeficiency Virus Preexposure Prophylaxis: Clinical Considerations and Caveats.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Article
- Current US Guidelines for Prescribing HIV Pre-exposure Prophylaxis (PrEP) Disqualify Many Women Who Are at Risk and Motivated to Use PrEP.Journal of acquired immune deficiency syndromes (1999) · 2019Article
- Pre-exposure Prophylaxis for HIV Infection: Preventing Disease or Promoting Sexual Health?Journal of community health · 2019Article
- Acceptability of Antiretroviral Pre-exposure Prophylaxis from a Cohort of Sexually Experienced Young Transgender Women in Two U.S. Cities.AIDS and behavior · 2018Article
- Prevalence of and Factors Associated with the Use of HIV Serosorting and Other Biomedical Prevention Strategies Among Men Who Have Sex with Men in a US Nationwide Survey.AIDS and behavior · 2018Article
- Development of rapid guidelines: 1. Systematic survey of current practices and methods.Health research policy and systems · 2018Article
- Inpatient Addiction Consult Service: Expertise for Hospitalized Patients with Complex Addiction Problems.The Medical clinics of North America · 2018Review
- How well are U.S. primary care providers assessing whether their male patients have male sex partners?Preventive medicine · 2018Article
- An overview of tenofovir and renal disease for the HIV-treating clinician.Southern African journal of HIV medicine · 2018Article
- HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults.AIDS patient care and STDs · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On June 12, 2013, the Thailand Ministry of Health and CDC published results from a randomized controlled trial of a daily oral dose of 300 mg of tenofovir disoproxil fumarate (TDF) that showed efficacy in reducing the acquisition of human immunodeficiency virus (HIV) infection among injecting drug users (IDUs) (1). Based on these findings, CDC recommends that preexposure prophylaxis (PrEP) be considered as one of several prevention options for persons at very high risk for HIV acquisition through the injection of illicit drugs.
Indexed as
Identifiers
23760186PMC4604844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.